NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · RVLPQ · USD
Stock price, earnings
Quote as of Oct 27, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
RVL Pharmaceuticals plc’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow RVL Pharmaceuticals plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults. The company, formerly known as Osmotica Pharmaceuticals plc, officially rebranded to RVL Pharmaceuticals plc in January 2022. Its corporate headquarters are situated in Bridgewater, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:47 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.08+66.42% vs estimate |
| $21.44M+155.72% vs estimate |
| Q3 2021 | Dec 30, 2021 | -$0.24 | $2.86M |
|---|
| Q2 2021 | Sep 29, 2021 | -$0.35 | $2.20M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
$0.03+$0.03 (+26,900.0%)
Vaxxinity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.5% below the high.
$0.00+$0.00 (+30.0%)
CNBX Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.43% below the high.
